#rare-disease-biotech
#rare-disease-biotech

[ follow ]

One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

Two rare-disease biotechs show diverging trajectories: Corcept has slower growth with high margins but thin operating profit, while Amicus achieves faster growth and sustainable profitability.

[ Load more ]

#rare-disease-biotech#rare-disease-biotech

One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

#rare-disease-biotech
#rare-disease-biotech